Stockscreener 앱 받기
0.9714
2.66%
0.0252
시간 외 거래:
.98
0.0086
+0.89%
전일 마감가:
$0.9462
열려 있는:
$0.9468
하루 거래량:
53,203
Relative Volume:
0.02
시가총액:
$13.39M
수익:
-
순이익/손실:
$-8.83M
주가수익비율:
-1.3285
EPS:
-0.7312
순현금흐름:
$-8.01M
1주 성능:
-2.86%
1개월 성능:
-19.05%
6개월 성능:
+0.14%
1년 성능:
-38.91%
1일 변동 폭
$0.94
$0.9891
1주일 범위
$0.94
$1.04
52주 변동 폭
$0.8588
$2.67
Cocrystal Pharma Inc Stock (COCP) Company Profile
명칭
Cocrystal Pharma Inc
전화
(786) 459-1831
주소
19805 N. CREEK PARKWAY, BOTHELL, WA
Compare COCP vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
0.9714 | 13.65M | 0 | -8.83M | -8.01M | -0.7312 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-07-08 | 개시 | H.C. Wainwright | Buy |
Cocrystal Pharma Inc 주식(COCP)의 최신 뉴스
Cocrystal Pharma Appoints New CEO to Lead Transition - The Globe and Mail
Cocrystal Pharma Appoints James Sapirstein as New CEO – Leadership Transition and Company Details - Minichart
Cocrystal Pharma appoints James Sapirstein as CEO with new compensation package - Investing.com India
James Sapirstein becomes CEO of Cocrystal Pharma (NASDAQ: COCP) - Stock Titan
Cocrystal Pharma Appoints James Sapirstein as Chief Executive Officer - Moomoo
Cocrystal Pharma taps longtime biotech exec as its new CEO - The Business Journals
Cocrystal Pharma Inc. (COCP) Q1 2026 Earnings: Wider-than-expected Loss as R&D Pipeline ProgressesEarnings Whisper Number - newsline.com
Cocrystal Pharma (COCP) CEO awarded 235,000 stock options under 2025 plan - Stock Titan
Cocrystal Pharma (COCP) CEO James Sapirstein files initial Form 3 - Stock Titan
Cocrystal Pharma names James Sapirstein as CEO - The Pharma Letter
Cocrystal Pharma Inc. Plans to Appoint James Sapirstein as A Member of the Board of Directors - marketscreener.com
Cocrystal Pharma Names New CEO to Drive Antiviral Pipeline - TipRanks
Cocrystal Pharma names James Sapirstein as new CEO By Investing.com - Investing.com South Africa
Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer - BioSpace
Cocrystal Pharma names James Sapirstein as new CEO - Investing.com
Veteran antiviral leader James Sapirstein to head Cocrystal Pharma (NASDAQ: COCP) - Stock Titan
Antiviral executive James Sapirstein takes helm at Cocrystal Pharma - Stock Titan
COCP: Presentation Highlights CDI-988 - Zacks Small Cap Research
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cocrystal Pharma (COCP) - The Globe and Mail
Noble Financial Maintains Cocrystal Pharma(COCP.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Cocrystal Pharma (COCP) proxy details board elections, pay and 2026 votes - Stock Titan
Cocrystal Pharma | 8-K: Current report - Moomoo
Cocrystal Pharma (COCP) Unveils Promising Antiviral Developments - GuruFocus
Cocrystal Pharma Reports Promising Pan-Viral Antiviral Activity - TipRanks
Cocrystal Pharma discovers new pan-viral inhibitors - BioWorld News
Cocrystal Pharma (NASDAQ: COCP) highlights pan-viral inhibitor data and Phase 1b progress - Stock Titan
Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza - GlobeNewswire
Deadly cruise ship hantavirus; Cocrystal runs lab tests on pan-viral blockers - Stock Titan
COCP Q1 2026 Earnings: Wider Loss Than Expected as Pre-Revenue Biotech Advances PipelineEarnings Revision Upgrade - The Legal Advocate
Cocrystal Pharma Stock Slips: Why COCP’s Norovirus Bet Is Back in Focus - Bez Kabli
Cocrystal (COCP) Q1 2026 Earnings Miss by Significant: Key TakeawaysMargin Compression Risk - Newser
Why Is Cocrystal Pharma, Inc. (COCP) Stock Down Today? - Meyka
Cocrystal Pharma, Inc. 2026 Q1 Financials: Company Overview, Segment Information, and Going Concern Risks - minichart.com.sg
Cocrystal (COCP) Declines -3.57% Amid Market Weakness 2026-05-15Market Neutral Pair - newser.com
Cocrystal Pharma Releases Q1 2026 Financial Results - AlphaStreet
Cocrystal Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cocrystal Pharma, Inc. 1Q 2026: Net loss $(2.30M), No revenue — 10-Q Summary - TradingView
Cocrystal Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Cocrystal Pharma, Inc. Quarterly Earnings Report - Stock Titan
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results - GlobeNewswire
Number of shareholders of Cocrystal Pharma, Inc. – NASDAQ:COCP - TradingView
Number of shareholders of Cocrystal Pharma Inc – LS:A3DWYX - TradingView
What Cocrystal (COCP) is building for next year | Q4 2025: EPS Exceeds ExpectationsSlow Growth - newser.com
Cocrystal Pharma Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
[EFFECT] Cocrystal Pharma, Inc. SEC Filing - Stock Titan
Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection - The Manila Times
Cocrystal Showcases Norovirus Candidate CDI-988 at ICAR 2026 - TipRanks
Cocrystal Pharma (COCP) advances Fast Track CDI-988 in Phase 1b norovirus challenge study - Stock Titan
No approved norovirus drugs; Cocrystal tests oral CDI-988 - Stock Titan
Cocrystal Pharma Presentation at ICAR 2026 Highlights - GlobeNewswire
COCP stock soars 75% — what is the link to Cocrystal’s norovirus treatment? - MSN
Cocrystal Pharma Inc (COCP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cocrystal Pharma Inc 주식 (COCP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | Director |
Feb 06 '26 |
Buy |
0.95 |
50,000 |
47,280 |
1,888,551 |
| FROST PHILLIP MD ET AL | Director |
Dec 31 '25 |
Buy |
0.95 |
50,000 |
47,275 |
1,838,551 |
| FROST PHILLIP MD ET AL | Director |
Dec 30 '25 |
Buy |
0.97 |
20,000 |
19,310 |
1,788,551 |
| FROST PHILLIP MD ET AL | Director |
Dec 26 '25 |
Buy |
0.97 |
40,000 |
38,944 |
1,768,551 |
| FROST PHILLIP MD ET AL | Director |
Dec 24 '25 |
Buy |
0.97 |
25,000 |
24,258 |
1,728,551 |
| FROST PHILLIP MD ET AL | Director |
Nov 26 '25 |
Buy |
0.99 |
4,000 |
3,975 |
1,703,551 |
| FROST PHILLIP MD ET AL | Director |
Nov 25 '25 |
Buy |
0.94 |
20,000 |
18,812 |
1,699,551 |
2.60%
0.94%
자본화:
|
볼륨(24시간):